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Summary
Background In early-stage HER2-positive breast cancer, escalation or de-escalation of systemic therapy is a controversial 
topic. As an aid to treatment decisions, we aimed to develop a prognostic assay that integrates multiple data types for 
predicting survival outcome in patients with newly diagnosed HER2-positive breast cancer.
Methods We derived a combined prognostic model using retrospective clinical–pathological data on stromal tumour-
infiltrating lymphocytes, PAM50 subtypes, and expression of 55 genes obtained from patients who participated in the 
Short-HER phase 3 trial. The trial enrolled patients with newly diagnosed, node-positive, HER2-positive breast cancer 
or, if node negative, with at least one risk factor (ie, tumour size >2 cm, histological grade 3, lymphovascular invasion, 
Ki67 >20%, age ≤35 years, or hormone receptor negativity), and randomly assigned them to adjuvant anthracycline 
plus taxane-based combinations with either 9 weeks or 1 year of trastuzumab. Trastuzumab was administered 
intravenously every 3 weeks (8 mg/kg loading dose at first c ycle, a nd 6  m g/kg t hereafter) f or 1 8 d oses o r w eekly 
(4 mg/kg loading dose in the first w eek, a nd 2  m g/kg t hereafter) f or 9  w eeks, s tarting c oncomitantly w ith t he fi rst 
taxane dose. Median follow-up was 91·4 months (IQR 75·1–105·6). The primary objective of our study was to derive 
and evaluate a combined prognostic score associated with distant metastasis-free survival (the time between 
randomisation and distant recurrence or death before recurrence), an exploratory endpoint in Short-HER. Patient 
samples in the training dataset were split into a training set (n=290) and a testing set (n=145), balancing for event and 
treatment group. The training set was further stratified into 100 iterations of Monte-Carlo cross validation (MCCV). 
Cox proportional hazard models were fit to MCCV training samples using Elastic-Net. A maximum of 92 features were 
assessed. The final prognostic model was evaluated in an independent combined dataset of 267 patients with early-
stage HER2-positive breast cancer treated with different neoadjuvant and adjuvant anti-HER2-based combinations and 
from four other studies (PAMELA, CHER-LOB, Hospital Clinic, and Padova) with disease-free survival outcome data.
Findings From Short-HER, data from 435 (35%) of 1254 patients for tumour size (T1 vs rest), nodal status 
(N0 vs rest), number of tumour-infiltrating lymphocytes (continuous variable), subtype (HER2-enriched and basal-
like vs rest), and 13 genes composed the final model (named HER2DX). HER2DX was significantly associated with 
distant metastasis-free survival as a continuous variable (p<0·0001). HER2DX median score for quartiles 1–2 was 
identified as the cutoff to identify low-risk patients; and the score that distinguished quartile 3 from quartile 4 was 
the cutoff to distinguish medium-risk and high-risk populations. The 5-year distant metastasis-free survival of the 
low-risk, medium-risk, and high-risk populations were 98·1% (95% CI 96·3–99·9), 88·9% (83·2–95·0), and 73·9% 
(66·0–82·7), respectively (low-risk vs high-risk hazard ratio [HR] 0·04, 95% CI 0·0–0·1, p<0·0001). In the 
evaluation cohort, HER2DX was significantly a ssociated w ith d isease-free s urvival a s a  c ontinuous v ariable 
(HR 2·77, 95% CI 1·4–5·6, p=0·0040) and as group categories (low-risk vs high-risk HR 0·27, 0·1–0·7, p=0·005). 
5-year disease-free survival in the HER2DX low-risk group was 93·5% (89·0–98·3%) and in the high-risk group 
was 81·1% (71·5–92·1).
Interpretation The HER2DX combined prognostic score identifies patients with early-stage, HER2-positive breast 
cancer who might be candidates for escalated or de-escalated systemic treatment. Future clinical validation of 
HER2DX seems warranted to establish its use in different scenarios, especially in the neoadjuvant setting.
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Introduction
HER2-positive breast cancer is responsible for a sub-
stantial proportion of deaths in women.1 In the early 
stages, adjuvant or neoadjuvant chemotherapy and 
anti-HER2 therapy (plus endocrine therapy in hormone 
receptor-positive disease) have consistently shown 
significant and long-term clinical benefits, in terms of 
disease-free survival and overall survival.1 However, 
substantial heterogeneity exists in HER2-positive disease 
regarding tumour biology,2–6 patients’ prognosis,7 and 
treatment benefit.7
Strategies to either escalate or de-escalate systemic 
therapy in early-stage HER2-positive breast cancer to 
improve survival outcomes have been explored,8 such as 
decreasing the number of cycles of chemotherapy9 and 
the duration of trastuzumab,10 increasing HER2 blockade 
with pertu zumab11 or neratinib,12 or switching anti-HER2 
therapy to trastuzumab emtansine in patients who did 
not achieve a pathological complete response following 
neoadjuvant trastuzumab-based chemotherapy.13 Despite 
these changes, most patients with early-stage, HER2-
positive breast cancer are cured with chemotherapy and 
trastuzumab.14
In early-stage hormone receptor-positive and HER2-
negative breast cancer, several prognostic tools allow better 
individualisation of systemic treatments and are widely 
available. For example, gene expression-based assays such 
as OncotypeDX (Genomic Health, Redwood City, CA, 
USA)15 help to identify low-risk patients who do not need 
adjuvant or neoadjuvant chemotherapy. Second-generation 
genomic tests, such as PAM50/Prosigna (NanoString 
Technologies, Seattle, WA, USA),16 which include clinical 
variables such as tumour size in the final risk assessment, 
might better distinguish patients who might not need 
chemotherapy from those who are likely to benefit.
Some variables beyond the tumour–node–metastasis 
classification have been associated with prognosis in 
early-stage, HER2-positive breast cancer—eg, staging 
before and after neoadjuvant therapy, hormone receptor 
status, number of stromal tumour-infiltrating lympho-
cytes,14,17,18 and PAM50 intrinsic subtypes.2,18,19 Similarly, 
these biomarkers and PIK3CA mutations20 have been 
associated with the probability of achieving a pathological 
complete response,20,21 which is also associated with a 
positive long-term outcome.22 However, decisions about 
escalation or de-escalation of systemic therapies are 
Research in context
Evidence before this study
We searched PubMed for clinical trials or studies published in 
English between Jan 1, 2010, and May 1, 2020, assessing 
HER2 inhibition in early-stage breast cancer, with the search 
terms “HER2+”, “early-stage”, “escalation”, “de-escalation”, 
“biomarker”, “breast cancer”, and “anti-HER2 therapy”. To date, 
several variables associated with survival outcome have been 
identified in early-stage, HER2-positive breast cancer, such as 
TNM staging before and after neoadjuvant therapy, hormone 
receptor status, tumour-infiltrating lymphocytes, 
PAM50 intrinsic subtype, and PIK3CA mutations. However, 
validation and clinical utility of these biomarkers, either alone 
or in combination, remains unknown.
International guidelines support the administration of 
adjuvant or neoadjuvant anti-HER2-based chemotherapy in 
patients with T1b–T4 or lymph-node positive disease. 
Since 2010 however, various strategies to either escalate or 
de-escalate systemic therapy in early-stage, HER2-positive 
breast cancer have been evaluated, such as (1) decreasing the 
amount of chemotherapy, (2) decreasing the duration of 
trastuzumab, (3) increasing HER2 blockade with either the 
addition of 1 year of pertuzumab to trastuzumab or the 
addition of 1 year of neratinib after trastuzumab, and 
(4) switching the type of anti-HER2 therapy to trastuzumab 
emtansine in patients who do not achieve a pathological 
complete response following neoadjuvant trastuzumab-based 
chemotherapy. Despite the successes and limitations of these 
treatment strategies, most patients with early-stage, 
HER2-positive breast cancer are cured with chemotherapy and 
trastuzumab; therefore, a multivariable prognostic tool to 
help guide systemic therapies in early-stage, HER2-positive 
breast cancer is needed.
Added value of this study
To our knowledge, ours is the first study attempting to build a 
combined prognostic score (called HER2DX) based on 
17 clinicopathological and genomic variables in early-stage, 
HER2-positive breast cancer, using tumour samples from a 
phase 3 clinical trial. Additionally, the prognostic score was 
evaluated in a combined neoadjuvant dataset of patients with 
newly diagnosed, HER2-positive breast cancer who received 
anti-HER2-based therapy, providing insights about the 
relationship between response to therapy in the neoadjuvant 
setting and long-term survival outcome.
Implications of all the available evidence
The evidence suggests that the HER2DX prognostic score 
identified a substantial proportion of patients with early-stage, 
HER2-positive breast cancer who might not need additional 
therapies, such as pertuzumab, neratinib, or trastuzumab 
emtansine because of their favourable survival outcomes with 
chemotherapy and trastuzumab (plus endocrine therapy if 
hormone receptor-positive). Further studies should establish 
the clinical use of the HER2DX prognostic score in this context 
and explore its value to help further de-escalate systemic 
treatments, such as the duration of trastuzumab or the amount 
of chemotherapy. Finally, multivariable prognostic models 
should be explored in other breast cancer subtypes, such as 
triple-negative disease, and other cancer types.
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based on nodal status, hormone receptor status, and 
therapy response.23 Therefore, a multivariable prognostic 
tool that integrates several variables to help guide 
systemic therapies in early-stage, HER2-positive breast 
cancer is urgently needed. Here, we aimed to develop 
such a prognostic tool based on multiple variables.
Methods
Study design and participants
This combined prognostic model was derived using 
retrospective clinical, pathological, and genomic data 
from a subset of patients who participated in the 
Short-HER trial. The final prognostic model was 
evaluated retrospectively in a combined and independent 
cohort of patients from four other studies (CHER-LOB, 
PAMELA, Hospital Clinic, and Padova) with early-stage, 
HER2-positive breast cancer.
Short-HER was a randomised, investigator-driven 
phase 3 study that aimed to assess the non-inferiority of 
9-week versus 1-year adjuvant trastuzumab combined
with chemotherapy in terms of disease-free survival
(primary endpoint) in women with HER2-positive breast
cancer.24 Briefly, eligible participants were women aged
18–75 years with surgically resected, HER2-positive breast
cancer with node positivity, or in case of node negativity, at 
least one of the following features: tumour size larger
than 2 cm, histological grade 3, presence of lymphovascular 
invasion, Ki67 greater than 20%, age 35 years or younger,
or hormone receptor negativity. 1254 patients with
an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0–1 were randomly assigned from
Dec 17, 2007, to Oct 6, 2013, to one of two treat ment
groups. The first group was assigned chemotherapy
consisting of intravenous doxorubicin 60 mg/m² or
intravenous epirubicin 90 mg/m² plus intravenous cyclo-
phos phamide 600 mg/m² every 3 weeks for four courses
followed by intravenous paclitaxel 175 mg/m² or docetaxel
100 mg/m² every 3 weeks for four courses. Trastuzumab
was administered intravenously every 3 weeks (8 mg/kg
loading dose at first cycle, and 6 mg/kg thereafter)
for 18 doses, starting with the first taxane dose. The
second group was assigned chemotherapy consisting of
intravenous docetaxel 100 mg/m² every 3 weeks for
three courses followed by intra venous fluorouracil
600 mg/m², epirubicin 60 mg/m², and cyclophosphamide
600 mg/m² every 3 weeks for three courses. Trastuzumab
was administered weekly (4 mg/kg loading dose in the
first week, and 2 mg/kg thereafter) for 9 weeks, starting
concomi tantly with docetaxel. When indicated, radio-
therapy and hormonal therapy were given according to
local standard care. Median follow-up was 91·4 months
(IQR 75·1–105·6), and distant metastasis-free survival
(the time between randomisation and distant recurrence
or death before recurrence) was an exploratory endpoint.
CHER-LOB25 was a randomised, non-comparative, 
investigator-driven phase 2 study done from Aug 8, 2006, 
to Nov 25, 2010, of preoperative taxane anthracycline 
consisting of intravenous paclitaxel (80 mg/m²) for 
12 weeks followed by intravenous fluorouracil, epirubicin, 
and cyclophosphamide for four courses every 3 weeks, in 
combination with intravenous trastuzumab, intravenous 
trastuzumab plus 1000 mg oral lapatinib (daily) or 
1500 mg lapatinib (daily) for 26 weeks in patients with 
HER2-positive, stage II to IIIA operable breast cancer 
and with a performance status of ECOG 0–1. The primary 
endpoint was to estimate the pathological complete 
response rate. Treatment after surgery was left to treating 
physician discretion. Median follow-up was 60·0 months 
(IQR 46·9–69·4), and disease-free survival (the time 
between treatment initiation and any of the following 
events, whichever occurred first: local, regional, and 
distant recurrence; contralateral breast cancer, other 
second invasive primary cancer, death before recurrence, 
or second primary cancer) was an exploratory endpoint.
PAMELA was a single-group, phase 2 trial done from 
Oct 22, 2013, to Nov 30, 2015, which aimed to assess the 
ability of the PAM50 HER2-enriched subtype to predict 
pathological complete response (the primary endpoint) 
at the time of surgery.21 Patients with HER2-positive 
breast cancer, stage I–IIIA, and an ECOG performance 
status of 0–1 were given oral lapatinib (1000 mg per day) 
and intravenous trastuzumab for 18 weeks; hormone 
receptor-positive patients were additionally given oral 
letrozole (2·5 mg per day) or oral tamoxifen (20 mg per 
day) according to menopausal status. Treatment after 
surgery was left to the treating physician’s discretion. 
Median follow-up was 68·1 months (IQR 57·1–72·3), 
and disease-free survival was an exploratory endpoint.
The Hospital Clinic and Padova University cohorts are 
consecutive series of patients with early-stage, HER2-
positive breast cancer and an ECOG perfor mance status 
of 0–1 treated as per standard practice from June 28, 2005, 
to Sept 26, 2018 (Hospital Clinic), and Feb 23, 2009, to 
May 26, 2016 (Padova University cohort), with neoadjuvant 
trastuzumab-based chemotherapy for 3–6 months, 
followed by surgery. Adjuvant treatment was completed 
with trastuzumab for up to 1 year. When indicated, 
radiotherapy and hormonal therapy were carried out 
according to local standard care. Median follow-up of the 
Hospital Clinic and Padova University cohorts were 39·3 
(IQR 29·6–55·8) and 38·5 (IQR 30·1–65·7) months, 
respectively. In both cohorts, disease-free survival was an 
exploratory endpoint. Approvals for the original studies 
were obtained from independent ethics committees.
Procedures
PAM50 and single gene analyses were done at the 
August Pi i Sunyer Biomedical Research Institute using 
formalin-fixed, paraffin-embedded tumours. Samples 
analysed from Short-HER were from surgical specimens, 
whereas samples analysed from the neoadjuvant cohorts 
from the other studies were from baseline samples 
before starting neoadjuvant therapy. A minimum of 
around 125 ng of total RNA was used to measure the 
expression of the 50 PAM50 subtype predictor genes and 
five other genes (CD8A, PD-L1, PD-1, CD4, and AR). 
Normalisation using housekeeping genes, and PAM50 
subtyping with adjustment factors, were done as pre-
viously described.21 For samples from CHER-LOB, 
PAM50 gene expression and subtyping values were 
obtained from PAM50-based microarray data (using the 
Affymetrix Human Genome U133 Plus 2.0 array) as 
previously described.26 All gene expression analyses were 
done blinded from clinical data. Nodal and tumour 
stages were obtained from clinical report forms. Finally, 
tumour-infiltrating lympho cytes, which consisted of all 
lymphocytic cell populations that had invaded the 
tumour tissue were assessed according to predefined 
criteria for the formalin-fixed paraffin-embedded tumour 
samples from all studies.27
Outcomes
The primary objective of this study was to derive and 
evaluate a combined prognostic score, named HER2DX, 
as a continuous variable. In the training dataset (ie, data 
from Short-HER), the chosen survival endpoint was 
distant metastasis-free survival, similar to studies of 
other gene expression-based prognostic biomarkers such 
as PAM50 risk of recurrence in hormone receptor-
positive, HER2-negative breast cancer.16 In the evaluation 
dataset, the survival end point was disease-free survival 
because of the availability of the data.
Our secondary objectives in the training and testing 
sets were (1) to describe the clinical–pathological and 
genomic features of the HER2DX risk groups; (2) to 
explore the association of HER2DX score with disease-
free survival in the evaluation dataset according to the 
type of pathological response; (3) to evaluate the 
association of HER2DX score with pathological complete 
response in the breast and axilla in the evaluation dataset. 
We also did an analysis of the association of HER2DX 
with disease-free survival in Short-HER.
Statistical analysis
For description purposes, 5-year estimates of distant 
metastasis-free survival, and 5-year and 8-year disease-
free survival estimates were calculated by Kaplan-Meier. 
The prognostic model was developed using a training 
dataset of patients enrolled in the Short-HER trial 
(appendix p 1). The rule to define a patient assessable in 
Short-HER was availability of gene expression, clinical–
pathological, and tumour-infiltrating lymphocytes data. 
Patients were divided into a training set and a testing set, 
balancing for distant metastasis-free survival events and 
treatment group. The training set was further stratified 
into 100 iterations of Monte-Carlo cross validation 
(MCCV). Cox proportional hazard models were fitted to 
MCCV training cases using elastic-net (package glmnet). 
A maximum of 92 features were evaluated. Elastic-net 
parameters (α and λ) were selected to reduce the partial 
likelihood of deviance and increase Harrell’s C-index 
evaluated in the MCCV test sets. These selected values 
were then used to fit our final model against the complete 
training set. A total of 17 variables were selected with the 
following survival coefficients: nodal stage N1–3 (0·680), 
tumour size T2–4 (0·339), MMP11 (0·200), PAM50 
HER2-enriched or basal-like (0·156), CDC6 (0·087), 
CDH3 (0·076), TMEM45B (0·048), EXO1 (0·024), FGFR4 
(0·021), RRM2 (0·008), number of tumour-infiltrating 
lymphocytes (–0·009), MLPH (–0·022), KRT5 (–0·024), 
KRT14 (–0·040), MYC (–0·050), PHGDH (–0·050), and 
BAG1 (–0·168).
Two cutoffs based on quartiles were defined to divide 
patients into low-risk (quartiles 1 and 2), medium-risk 
(quartile 3), and high-risk (quartile 4) groups. The final 
model was tested, as a continuous variable and using the 
prespecified cutoffs, in 267 patients from the evaluation 
dataset (appendix p 2). The evaluation dataset was 
composed of patients with gene expression, clinical–
pathological, and tumour-infiltrating lymphocytes data 
from the CHER-LOB and PAMELA studies, and the 
Padova and Hospital Clinic cohorts. Missing data were 
not included in our analyses.
Cox proportional hazard regression analyses were used 
to investigate the association of each variable with 
survival outcome. Genes associated with the HER2DX 
risk groups were identified using a multiclass signifi-
cance analysis of microarrays and a false discovery rate of 
less than 5%. Categorical variables were expressed as 
number (%) and compared between low-risk and 
medium to high-risk HER2DX groups by χ² test or 
Fisher’s exact test. Continuous variables were compared 
by Student’s t test. Logistic regression analyses were 
done to investigate the association of each variable with 
pathological complete response. The significance level 
was set to a two-sided α of 0·05. The software used for all 
statistical analyses was R version 3.6.2.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study and had final responsibility for the 
decision to submit for publication.
Results
To build a prognostic model, clinical–pathological and 
molecular data were available from 435 (35%) of 
1254 patients in the Short-HER trial (table 1). 290 (67%) 
patients were placed in the training set and 145 (33%) in 
the testing set. Mean age was 55·4 (SD 10·2) and most 
tumours were 2 cm or less (T1 stage), node-negative 
(N0 stage), hormone receptor-positive, histological grade 3, 
and had 29% or less tumour-infiltrating lympho cytes.
Most tumours were PAM50 HER2-enriched and the 
proportion of HER2-enriched breast cancer was higher 
in hormone receptor-negative disease (126 patients 
[70%]) compared with hormone receptor-positive 
See Online for appendix
disease (309 [46%]). As expected, most luminal A or B 
and basal-like subtypes were hormone receptor-positive 
(309 [99%]) and hormone receptor-negative (126 [70%]), 
respectively.
A multivariable Cox model analysis of distant 
metastasis-free survival on the dataset from the 
435 patients in Short-HER trial showed that tumour size, 
nodal status, percentage of tumour-infiltrating lympho-
cytes, and PAM50 subtypes were independent prognostic 
variables (appendix p 3). Next, we evaluated the ability of 
31 variables to provide additional prognostic information 
using cross-validated elastic-net Cox models. The final 
HER2DX score included 17 variables: tumour size 
(T1 vs rest), nodal status (N0 vs rest), number of tumour-
infiltrating lymphocytes (as a continuous variable), 
PAM50 subtype (HER2-enriched and basal-like vs rest), 
and 13 individual genes (appendix pp 13–16). Seven (54%) 
of these genes had coefficients associated with poor 
distant metastasis-free survival outcome and were mostly 
















·· ·· ·· 0·0001
0–29% 379 (87%) 176 (81%) 203 (94%) ··
≥30% 56 (13%) 42 (19%) 14 (7%) ··
Primary tumour 
stage
·· ·· ·· <0·0001
T1 235 (54%) 157 (72%) 78 (36%) ··
T2–4 200 (46%) 61 (28%) 139 (64%) ··
Nodal status ·· ·· ·· <0·0001
N0 264 (61%) 187 (86%) 77 (36%) ··
N1–3 171 (39%) 31 (14%) 140 (65%) ··
PIK3CA 
mutations
·· ·· ·· 1·000
Wild type 339 (78%) 169 (78%) 170 (78%) ··
Mutated 92 (21%) 46 (21%) 46 (21%) ··
NA 4 (1%) 3 (1%) 1 (1%) ··
Hormone 
receptor status
·· ·· ·· 0·092
Positive 309 (71%) 163 (75%) 146 (67%) ··
Negative 126 (29%) 55 (25%) 71 (33%) ··











213 (49%) 104 (48%) 109 (50%) ··
Grade ·· ·· ·· 0·25
1 6 (1%) 5 (2%) 1 (1%) ··
2 115 (27%) 58 (27%) 57 (27%) ··
3 309 (72%) 152 (71%) 157 (73%) ··
PAM50 ·· ·· ·· <0·0001
Luminal A 87 (20%) 63 (29%) 24 (11%) ··
Luminal B 43 (10%) 24 (11%) 19 (9%) ··
HER2-enriched 230 (53%) 75 (34%) 155 (71%) ··
Basal-like 27 (6%) 17 (8%) 10 (5%) ··
Normal-like 48 (11%) 39 (18%) 9 (4%) ··
Data are mean (SD) or n (%). NA=not assessed. *p values represent the 
comparison between the HER2DX combined prognostic score low-risk group and 
the medium-risk to high-risk group.





























































Low risk vs medium risk HR 0·11 (95% CI 0·0–0·3); p<0·0001
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Figure 1: Distant metastasis-free survival outcomes based on HER2DX combined prognostic scores in the 
Short-HER training dataset
(A) Distant metastasis-free survival according to low-risk (quartiles 1 and 2 combined), medium-risk (quartile 3) 
and high-risk (quartile 4) scores. (B) Distant metastasis-free survival according to low-risk (quartiles 1 and 2 
combined) and medium or high-risk (quartiles 3 and 4 combined) scores. HR=hazard ratio.
RRM2), HER2-enriched-related biology (TMEM45B 
and FGFR4) and basal-like-related biology (CDH3). The 
other six (46%) genes had survival coefficients asso-
ciated with better outcome and were mostly tracking 
luminal A-related biology (BAG1), normal-like biology 
(KRT5, KRT14, MLPH, and MYC), and basal-like-related 
biology (PHGDH). The predictive performance (C-index) 
of HER2DX in Short-HER was 0·80 for all patients, 
0·83 for the training set, and 0·72 for the testing set from 
Short-HER.
HER2DX measured as a continuous variable was 
significantly associated with distant metastasis-free 
survival in the Short-HER 435 patient-dataset (p<0·0001). 
According to HER2DX scoring based on quartiles 
(appendix p 4), the 5-year distant metastasis-free survival 
of quartiles 1, 2, 3, and 4 were 97·1% (95% CI 94·0–100·0), 
99·1% (97·3–100·0), 88·9% (83·2–95·0), and 73·9% 
(66·0–82·7), respectively. There was no significant 
difference in distant metastasis-free survival between 
quartile 2 versus quartile 1 (hazard ratio [HR] 0·92, 
95% CI 0·23–3·70, p=0·91). Quartiles 3 and 4 had 
significantly worse distant metastasis-free survival 
compared with quartile 1 (quartile 3: HR 4·57, 95% CI 
1·5–13·6, p=0·010; quartile 4: 12·0, 4·30–33·5, p<0·0001).
Based on these findings, HER2DX median score 
(ie, quartiles 1–2) was identified as the cutoff to identify 
low-risk patients (figure 1). The 5-year distant metastasis-
free survival of the low-risk group was 98·1% (95% CI 
96·3–99·9; figure 1). The HER2DX score that distin-
guished quartile 3 from quartile 4 was designated as the 
cutoff to identify medium-risk and high-risk patients. 
5-year distant metastasis-free survival was 88·9%
(95% CI 83·2–95·0) in the medium-risk group and
73·9% (66·0–82·7) in the high-risk group. The low-risk
group (quartiles 1–2) had signifi cantly longer distant
metastasis-free survival compared with the high-risk
group (quartile 4), the medium-risk group (quartile 3),
and the medium-risk to high-risk group (quartiles 3–4;
figure 1). An analysis of HER2DX versus disease-free
survival showed similar results (appendix p 4).
Clinical–pathological and molecular features of the 
HER2DX low-risk patients in Short-HER were compared 
with those of the medium-risk to high-risk patients 
(table 1). No clinical–pathological or molecular feature 
was unique to HER2DX low-risk patients. Similarly, 
7–36% of HER2DX medium to high-risk patients had 
features associated with a better survival outcome, such 
as a high percentage of tumour-infiltrating lymphocytes 
(>30%), T1 tumours, or node-negative disease (table 1).
41 (75%) of 55 genes analysed in total were found 
differentially expressed across the three risk groups 
(appendix p 5).
A dataset of 267 patients with early-stage HER2-positive 
disease obtained from a combined cohort of four neo-
adjuvant studies was used for an independent evaluation 
of the HER2DX score (the score was determined at 
baseline before starting neoadjuvant therapy; table 2). 
The evaluation dataset was composed of 74 (61%) of 
121 patients from CHER-LOB, 88 (58%) of 151 from 
PAMELA, 37 from the Padova cohort and 68 from the 
Hospital Clinic cohort. All patients received chemo-
therapy and 1 year of trastuzumab; 116 (43%) of 
267 patients received dual HER2 blockade with lapatinib 
and trastuzumab for 4·5 to 6·0 months, and 20 (8%) 








to high risk 
(n=150)
p value*




·· ·· ·· 0·0090
0–29% 220 (82%) 88 (75%) 132 (88%) ··
≥30% 47 (18%) 29 (25%) 18 (12%) ··
Clinical tumour 
stage
·· ·· ·· 0·010
T1 57 (21%) 34 (29%) 23 (15%) ··
T2–4 210 (79%) 83 (71%) 127 (85%) ··
Clinical nodal 
status
·· ·· ·· <0·0001
N0 148 (55%) 101 (86%) 47 (31%) ··
N1–3 119 (45%) 16 (14%) 103 (69%) ··
Pathological 
response
·· ·· ·· 0·90
Complete 
response
98 (37%) 42 (36%) 56 (37%) ··
Residual 
disease
169 (63%) 75 (64%) 94 (63%) ··
Hormone 
receptor status
·· ·· ·· 0·0001
Positive 172 (64%) 91 (78%) 81 (54%) ··
Negative 95 (36%) 26 (22%) 69 (46%) ··
Grade ·· ·· ·· 0·34
1 15 (6%) 5 (5%) 10 (7%) ··
2 71 (28%) 35 (32%) 36 (25%) ··
3 168 (66%) 68 (63%) 100 (69%) ··
PAM50 ·· ·· ·· <0·0001
Luminal A 51 (19%) 38 (33%) 13 (9%) ··
Luminal B 33 (12%) 20 (17%) 13 (9%) ··
HER2-
enriched
138 (52%) 35 (30%) 103 (69%) ··
Basal-like 21 (8%) 7 (6%) 14 (9%) ··
Normal-like 24 (9%) 17 (15%) 7 (5%) ··
Study ·· ·· ·· 0·37
PAMELA 88 (33%) 33 (28%) 55 (37%) ··
CHER-LOB 74 (28%) 38 (33%) 36 (24%) ··
Hospital Clinic 68 (26%) 30 (26%) 38 (25%) ··
Padova 37 (14%) 16 (14%) 21 (14%) ··
Data are mean (SD) or n (%). *p values represent the comparison between the 
HER2DX combined prognostic score low-risk group and the medium-risk to high-
risk groups.
Table 2: Baseline characteristics of the combined patient evaluation 
dataset
Despite hetero geneity in systemic therapies, there were 
no significant differences in disease-free survival across 
the four cohorts (appendix p 6).
In the evaluation dataset, HER2DX score as a con-
tinuous variable was significantly associated with 
disease-free survival (HR 2·77, 95% CI 1·4–5·6, 
p=0·0040; appendix pp 7, 17). According to the 
prespecified cutoffs, the HER2DX low-risk group had 
longer disease-free survival than the medium-risk to 
high-risk group or the high-risk group (figure 2). 5-year 
disease-free survival in the HER2DX low-risk, high-risk, 
and medium-risk to high-risk groups was 93·5% (95% CI 
89·0–98·3), 81·1% (71·5–92·1), and 86·7% (81·2–92·5), 
respectively. 8-year disease-free survival in the HER2DX 
low-risk, high-risk, and medium to high-risk groups 
was 91·7% (95% CI 86·2–97·6%), 54·1% (24·1–100), and 
78·7% (62·6–98·9), respectively.
Tumour-infiltrating l ympho c ytes as a continuous 
variable (odds ratio [OR] 1·04, 95% CI 1·0–1·1, p<0·0001) 
and HER2-enriched subtype (OR 3·25, 95% CI 1·8–5·7, 
p<0·0001) were associated with pathological complete 
response in the evaluation cohort. On the contrary, 
HER2DX score as a con tinuous variable was not 
associated with pathological complete response (OR 1·02, 
95% CI 0·6–1·6, p=0·93) in the evaluation cohort. 
According to the previously described cutoffs, the pro-
portion of patients who achieved a pathological complete 
response in the evaluation cohort in the HER2DX low-
risk, medium-risk, and high-risk groups were 42 (36%) of 
117 patients, 34 (39%) of 86 patients and 22 (36%) of 
64 patients. Among 169 patients with residual disease in 
the evaluation cohort, the distribution of HER2DX low-
risk, medium-risk, and high-risk groups was 75 (44%), 
52 (31%), and 42 (25%), respectively. In this setting of 
patients with residual disease, the HER2DX low-risk 
group had longer disease-free survival compared with 
the high-risk group (HR 0·34, 95% CI 0·1–0·9, p=0·030) 
but not the medium-risk group (0·63, 0·2–1·7, p=0·38) 
or the medium-risk to high-risk group (0·47, 0·2–1·1, 
p=0·10; appendix pp 7–12). In patients with residual 
disease, 5-year disease-free survival in the HER2DX 
low-risk and high-risk groups was 90·0% (95% CI 
83·2–97·4) and 78·2% (65·6–93·2), respectivel. 8-year 
disease-free survival in the HER2DX low-risk and high-
risk groups was 87·6% (95% CI 79·7–96·3) and 39·1% 
(0·1–100·0), respectively. Of 98 patients who achieved a 
pathological complete response, the distri bution of 
HER2DX low-risk, medium-risk, and high-risk groups 
was 42 (42·9%), 34 (34·7%), and 22 (22·4%), respectively.
Discussion
To our knowledge, this is the first s tudy a ttempting t o 
build a combined prognostic score based on 17 clinical–
pathological and genomic variables in early-stage, HER2-
positive breast cancer using tumour samples from a 
phase 3 trial. Specifically, our results showed that HER2DX 
is associated with long-term distant metastasis-free 
survival and can identify groups of patients with different 
risks of relapsing following standard therapy. Additionally, 
our study provided insights about the relation ship between 
response to therapy in the neo adjuvant setting and long-
term prognosis. From a clinical point of view, HER2DX 
could identify patients with early-stage, HER2-positive 
disease who are candidates for escalated or de-escalated 
systemic treatment. Future validation of HER2DX seems 
warranted.
Escalation or de-escalation of systemic therapies in 
early-stage, HER2-positive disease is a controversial 
topic. In stage 1 disease, the APT trial28 showed disease-
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Figure 2: Disease-free survival outcomes based on HER2DX combined prognostic scores in the combined 
evaluation dataset
(A) Disease-free survival according to low-risk (quartiles 1 and 2 combined), medium-risk (quartile 3) and high-risk 
(quartile 4) scores. (B) Disease-free survival according to low-risk (quartiles 1 and 2 combined) and medium or 
high-risk (quartiles 3 and 4 combined) scores. HR=hazard ratio.
adjuvant paclitaxel plus 1 year of trastuzumab in a single-
arm trial of 410 patients. This treatment strategy is now 
widely adopted,28 although controversy exists in patients 
with hormone receptor-negative disease.29 Regarding 
de-escalation of trastuzumab, several non-inferiority 
studies, including the Short-HER trial,22 have shown a 
narrow reduction in recurrence risk with 12 months of 
therapy compared with shorter durations.10,28,29 This 
treatment strategy, however, has not been widely adopted 
worldwide, despite its potential impact in low-income 
countries where trastuzumab is not reimbursed.23
In stage 2–3 disease, escalated systemic treatments with 
pertuzumab, neratinib, and trastuzumab emtansine are 
approved by the US Food and Drug Administration and 
the European Medicines Agency.11–13 However, the absolute 
benefit of pertuzumab and neratinib is low (<3% in 
invasive disease-free survival).11,12 Trastuzumab emtansine, 
contrarily, has shown clinically meaningful results with 
an absolute increase in invasive disease-free survival at 
3 years of 11·3% compared with trastuzumab in patients 
with HER2-positive breast cancer who do not achieve 
a pathological complete response following standard 
anti-HER2-based chemo therapy.13 However, three of 
four patients in the control group of this pivotal trial13 did 
not have an event at 3 years. Overall, there is an urgent 
need to better define the populations of patients with 
early-stage, HER2-positive disease who are candidates for 
escalated or de-escalated systemic therapies.
To our knowledge, our study is the first to report a 
clinically valuable prognostic biomarker in HER2-positive 
breast cancer. Specifically, the HER2DX score can divide 
the population of early-stage, HER2-positive breast cancer 
into two prognostically distinct groups. To accomplish 
this, the assay integrates multiple data types and presents 
a single prognostic score as a continuous variable and 
proposes specific cutoffs. Importantly, the HER2DX low-
risk group cannot be identified by classic clinical and 
pathological variables, and a substantial proportion of 
HER2DX low-risk patients have individual features 
known to be associated with poor survival outcome, such 
as a large tumour size, nodal positivity, a low number of 
tumour-infiltrating lymphocytes, and residual disease 
after neoadjuvant therapy. Finally, an intriguing finding is 
that HER2DX is not associated with the probability to 
achieve a pathological complete response following anti-
HER2-based therapy.
Our study had several limitations. First, the evaluation 
dataset was a heterogeneous cohort of patients. Second, 
the survival endpoint from the training dataset (ie, distant 
metastasis-free survival) was different from the evalu ation 
dataset (ie, disease-free survival), because PAMELA had 
disease-free survival data recorded, not distant metastasis-
free survival. Third, the CIs of the survival estimates at 
5 years and 8 years of the different risk groups overlap. 
Fourth, a substantial proportion of patients in the 
evaluation dataset also received dual HER2 blockade with 
lapatinib and trastuzumab. However, the absolute effect of 
dual HER2 blockade with these two drugs in terms of 
survival outcomes was small (ie, absolute increase 
compared with trastuzumab of 2% at 4 years).30 Fifth, 
HER2DX was developed from primary tumour specimens 
and staging was based on surgical pathology reports. This 
approach is different from the neoadjuvant setting where 
a core biopsy is the only available tissue and staging is 
based on imaging. Despite this limitation, HER2DX did 
well in the combined neoadjuvant dataset, suggesting it 
can predict outcome at diagnosis before any treatment is 
initiated using core biopsies. Sixth, the Short-HER cohort 
was powered for another primary endpoint, which was to 
compare disease-free survival between two treatment 
groups. However, the analysis presented here used all 
available patients from this study. Thus, we did not do a 
formal power analysis and focused on significant results. 
Finally, the HER2DX assay is not standardised and specific 
cutoffs will need to be defined.
Following our results, the question remains whether 
HER2DX will guide the use of systemic therapy in early-
stage HER2-positive breast cancer. Our opinion is that 
we are not ready yet to embrace this biomarker and 
further validation studies should establish its clinical use 
in different scenarios with a particular focus in the neo-
adjuvant setting, where the type of pathological response 
might be incorporated in the HER2DX algorithm. To 
accomplish this, the HER2DX assay should be standard-
ised and applied retrospectively in tumour samples from 
at least two large and completed phase 3 pivotal clinical 
trials such as APHINITY,11 NeoALTTO,30 ExteNET,12 
PERSEPHONE, or KATHERINE.13 For example, patients 
with HER2DX low-risk disease at diagnosis who do not 
achieve a pathological complete response following anti-
HER2-based neoadjuvant therapy could be spared 
14 cycles of adjuvant trastuzumab emtansine. Finally, 
HER2DX could help the design of prospective clinical 
trials to test novel escalation or de-escalation treatment 
strategies.
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